Ter Arkh. 2000;72(12):7-10.

[Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia].

[Article in Russian]

Nikitin IuP, Slepchenko NV, Gratsianskiĭ NA, Nechaev AS, Syrkin AL, Poltavskaia MG, Sumarokov AV, Revazov AV.

Abstract

AIM:

To compare efficacy and tolerance of polycosanol vs besafibrate in patients with hypercholesterolemia (HCE).

MATERIAL AND METHODS:

A multicenter controlled double blind randomised trial entered 113 patients with HCE. After 5 weeks of diet the patients were randomised into two groups. 59 patients of group 1 received polycosanol (10 mg/day), 54 patients of group 2 were given besafibrate (400 mg/day) for 8 weeks.

RESULTS:

The 8-week course of treatment was completed by 103 patients (91%): 57(97%) patients of group 1 and 46(85%) patients of group 2. In group 1 total cholesterol diminished by an average of 15%, LDLP cholesterol fell by 18%, triglycerides by 15%, while in group 2 a respective decrease was 8, 11 and 6%. Side effects in group 1 were mild.

CONCLUSION:

A hypolipidemic effect of polycosanol in a daily dose 10 mg is superior to that of besafibrate in a daily dose 400 mg.

PMID:: 11201841; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

Supplemental Content

Save items

Related citations in PubMed

Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. [Drugs R D. 2005]
Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
Castaño G, Fernández L, Mas R, Illnait J, Gámez R, Mendoza S, Mesa M, Fernández J. Drugs R D. 2005; 6(4):207-19.
Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. [Int J Clin Pharmacol Res. 2001]
Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G, Mas R, Fernández L, Illnait J, Gámez R, Alvarez E. Int J Clin Pharmacol Res. 2001; 21(1):43-57.
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. [Am J Cardiovasc Drugs. 2009]
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A, Study Investigators. Am J Cardiovasc Drugs. 2009; 9(2):91-101.
Review ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524. [Drugs R D. 2007]
Review ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
[No authors listed]Drugs R D. 2007; 8(2):103-12.
Review [Familial hypercholesterolemia. Screening, prevention and therapeutic possibilities]. [Minerva Pediatr. 1982]
Review [Familial hypercholesterolemia. Screening, prevention and therapeutic possibilities].
Vierucci A, Biadaioli R, De Martino M, Pratesi F, Novembre E, Morotti P. Minerva Pediatr. 1982 Apr 30; 34(8):325-36.

See reviews... See all...

Cited by 1 PubMed Central article

Policosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial. [Altern Ther Health Med. 2011]
Policosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial.
Swanson B, Keithley JK, Sha BE, Fogg L, Nerad J, Novak RM, Adeyemi O, Spear GT. Altern Ther Health Med. 2011 Mar-Apr; 17(2):30-5.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

[Results of the multicenter controlled study of the hypolipidemic drug polycosan...
[Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia].
Ter Arkh. 2000 ;72(12):7-10.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: